The Lead Episode 76: A Discussion of Asundexian versus Apixaban in Patients with Atrial Fibrillation-The Lead Episode 76 Bonus Video

Video Transcription

Video Summary

In this episode of The Lead from HRX Atlanta, hosted by the Digital Education Committee of the Heart Rhythm Society, Melissa Middeldorp, Prash Sandesh, and Chris Chung discuss the OCEANIC trial comparing Ascendexion (a Factor XI inhibitor) to Epixaban in atrial fibrillation patients. The trial, sponsored by Bayer, was stopped early at 14,810 participants due to higher stroke and embolism rates in the Ascendexion group. Despite showing lower bleeding rates, the trial's results emphasize the need for randomized clinical trials and further analysis to refine anticoagulation therapies and dosing strategies.

Keywords

OCEANIC trial

atrial fibrillation

Factor XI inhibitor

anticoagulation therapies

clinical trials